Overall, the literature supports the argument that SGLT2-Is reduce HF events, at least in part, via improved vascular function, considering that central systolic blood pressure is primarily determined by arterial stiffness of large arteries and an important surrogate parameter afterload strongly linked to future CV outcomes [255]. Here, SLC5A2 is linked to hydrops fetalis.